CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in collaboration with Moderna on an mRNA encoded masked IL-12 molecule. The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, being held in Chicago, IL on April 25-30, 2025. “We are excited to share new preclinical data at AACR, establishing proof of concept for an mRNA encoded masked molecule in the treatment of cancer,” said Marcia Belvin, Ph.D. SVP, Chief Scientific Officer of CytomX Therapeutics. “IL-12 has shown promising anti-tumor activity, but its clinical use has been limited due to its inflammatory toxicity and narrow therapeutic window. By combining CytomX’s proprietary PROBODY® masking technology and Moderna’s mRNA technology, we have created an mRNA therapeutic encoding a masked IL-12, designed to be selectively activa
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress [Yahoo! Finance]Yahoo! Finance
- CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling [Seeking Alpha]Seeking Alpha
- What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CTMX's page on the SEC website